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Background: It has been reported that oxidation product of cholesterol, 7-ketocholesterol, increases in plasma of
patients with NP-C. Previously, we established a rapid test to determine the plasma 7-ketocholesterol level and
found it elevated significantly in patients with acid sphingomyelinase deficient NPD and NP-C disease.
Methods: Individuals randomly referred to our outpatient clinics in the past two years for hepatosplenomegaly or
isolated splenomegaly, who have been excluded as acid sphingomyelinase deficient NPD or Gaucher disease,
and individuals with newborn cholestasis, psychomotor regression/retardation, were screened for plasma
7-ketocholesterol level. Individuals with high 7-ketocholesterol level were then analyzed for NPC1 and NPC2 gene
mutation to confirm the accuracy of NP-C diagnosis.
Results: By screening the plasma 7-ketocholesterol of suspect individuals, 12 out of 302 (4%) had shown remarkable
high levels compared with reference. All these twelve individuals were subsequently confirmed to be NP-C by DNA
analysis of NPC1 and NPC2 genes, with the early infantile form (n = 7), the late infantile form (n = 1), the juvenile
form (n = 1) and the adult form (n = 1). Furthermore, two NP-C patients without observable neuropsychiatric
disability were picked up through this procedure. Only one patient had NP-C due to NPC2 gene mutations, with
the rest due to NPC1 gene mutations. We found that in NP-C patients AST was usually mildly elevated and ALT was
in a normal range when jaundice was not present. In total, 22 mutant alleles were identified in the NPC1 gene,
including six novel small deletions/insertions, e.g., c.416_417insC, c.1030delT, c.1800delC, c.2230_2231delGT,
c.2302_2303insG, and c.2795dupA; seven novel exonic point mutations, c.1502A>T (p.D501V), c.1553G>A (p.R518Q),
c.1832A>G (p.D611G), c.2054T>C (p.I685T), c.2128C>T(p.Q710X), c.2177G>C (p.R726T), c.2366G>A (p.R789H), and one
novel intronic mutation c.2912-3C>G. Small deletions/insertions constituted nearly half of the mutant alleles (10/22,
45%), indicating a unique mutation spectrum in this cohort of Chinese NP-C patients.
Conclusion: Our data confirm in a clinical setting that screening plasma 7-ketocholesterol is an efficient and
practical diagnostic tool to identify NP-C patients from suspect individuals. Patients without neuropsychological
involvement could also be identified by this method therefore allowing an opportunity for earlier treatment.
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Niemann-Pick disease type C (NP-C, OMIM 257220,
607625) is a rare autosomal recessive disease belonging
to the family of lysosomal storage disorders. Mutations
in one of two lysosome-related genes have been identi-
fied as accounting for the occurrence of this disease.
One is a large lysosomal integral membrane protein NPC1
[1], which transfers low density lipoprotein-derived free
cholesterol out of lysosomes or late endosomes [2]. The
other is a small lysosomal soluble protein NPC2 [3], which
functions in concert with NPC1 [4]. Defects of these two
proteins result in sequestration of mainly unesterified
cholesterol, as well as other sphingolipids in the late endo-
somes/lysosomes at the cellular level, ultimately leading to
a clinical neurovisceral manifestation characterized by
hepatosplenomegaly and severe progressive neurological
dysfunction, which includes vertical supranuclear gaze
palsy, ataxia, dystonia, dysarthria, dysphagia, gelastic
cataplexy, and epileptic seizures. According to age at
onset of neurological manifestations, NP-C patients are
categorized into five forms, i.e., perinatal, early-infantile,
late-infantile, juvenile, and adult forms [5].
Clinical manifestations of NP-C are usually not disease-
specific and are extremely variable. Taking the perinatal
form as an example, newborns with this form of NP-C
typically have cholestasis and hepatosplenomegaly. At a
North American medical centre, in all infants evaluated
for neonatal cholestasis, NP-C was identified in 8% of
them, with the rest being affected by other disorders [6].
In a multicentre genetic screening study evaluating the
frequency of NP-C among patients who shared common
neurological and psychiatric symptoms, only three of
256 adults (1.2%) were confirmed to be NP-C [7]. In the
literature NP-C has been misdiagnosed as Wilson dis-
ease [8] and Gaucher disease [9]. Generally, there was a
long lag time between the initial onset of neurological
manifestations and definite diagnosis [10]. Miglustat has
been shown to be an effective therapy for NP-C [11]
and a new drug, 2-hydroxypropyl-beta-cyclodextrin
(Cyclodextrin), is being tested in a clinical trial for this
disease. Earlier treatment with Miglustat has been
shown to be associated with a better prognosis [12].
Thus, prompt and accurate diagnosis is becoming in-
creasingly important.
NP-C is pan ethnic and is estimated with an incidence of
1:120,000 live births [2,13]. Numerous patients have been
reported in Western countries [10,14-16], but only approxi-
mately 10 Chinese patients have been confirmed to have
this disorder [17,18]. It is highly likely that a large portion
of Chinese NP-C patients are undiagnosed, which is pos-
sibly due to both the extremely variable presentation of
NP-C and the complex procedure used to biochemically
demonstrate abnormal intracellular cholesterol homeostasis
in cultured fibroblasts.It was reported that cholesterol oxidation products,
7-ketocholesterol (7-KC) and cholestan-3β,5α,6β-triol
(3β,5α,6β-triol), were markedly increased in the plasma
of human NPC1 subjects; therefore, these products
could be used as non-invasive and highly sensitive bio-
markers for NP-C disease [19,20]. But the diagnostic
value of these biomarkers has not been evaluated in the
clinical settings. Previously, we established a method for
rapid plasma 7-KC detection [21], and found that high
7-KC levels could not differentiate between acid sphin-
gomyelinase (ASM) deficiency and NP-C. Clinically,
ASM deficiency belongs to the differential diagnosis of
NP-C, at least at a certain stage of the disease. High 7-
KC levels in patients with systemic symptoms indicate
the patients should be further analyzed for ASM activity
test, followed by SMPD1 gene mutation test in case of
deficient ASM activity, or NPC1/NPC2 gene mutation
test in case of normal ASM activity .
We have set up an ASM activity test to diagnose ASM
deficiency in our lab among individuals with hepatos-
pleomagaly or isolated splenomegaly [22]. We speculated
that there may be NP-C patients in those without a clear
diagnosis after ASM and glucocerebrosidase assay. So
we use the biomarker 7-KC to screen these patients, as
well as newborns with cholestasis, and individuals re-
ferred to our centre for psychomotor regression/retard-
ation. Individuals with elevated 7-KC were followed by
molecular genetic testing of NPC1 and NPC2 genes to
confirm the diagnosis. Here we report the clinical and
molecular characteristics of 12 new Chinese NP-C pa-
tients identified through this procedure in the past two
years.
Materials and methods
Compliance with ethics guidelines
All procedures were in accordance with the ethical stan-
dards of committee on human experimentation in
Shanghai Xinhua hospital (approval number XHEC-D-
2011-017) and with the Helsinki Declaration of 1975, as
revised in 2012. Informed consent was obtained from
each patient for inclusion in the study.
Indications to be included in 7-KC screening
Individuals randomly referred to our department for
newborn cholestasis (group A), hepatosplenomegaly/
hepatomegaly/splenomegaly (group B), psychomotor re-
gression/retardation (group C), in the past two years
were recruited to join this study. Patients with hepatos-
plenomegaly or isolated splenomegaly were analysed to
exclude acid sphingomyelinase deficient Niemann-Pick
disease and Gaucher disease by measuring acid sphingo-
myelinase and glucocerebrosidase enzyme activity of
peripheral blood leukocytes before determination of
plasma 7-KC levels. Infants with sustained cholestasis,
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megaly were classified to group A; Individuals with
hepatosplenomegaly/hepatomegaly/splenomegaly with
or without a history of newborn jaundice were classified
to group B; Individuals with hepatosplenomegaly/hep-
atomegaly/splenomegaly followed by psychomotor re-
gression/retardation were also classified to group B;
patients dominated with psychomotor regression/re-
tardation, without palpable hepatosplenomegaly were
classified to group C. There were 11 infants in group A,
124 patients in group B, and 167 patients in group C. As
for the age, there were 45 individuals 15 years and older,
62 between 6 and 15 years old, 79 between 2 and 6 years
old, 104 individuals between 3 months and 2 years old,
and 12 under 3 months old.
Plasma 7-KC levels
The plasma 7-KC level was evaluated as previously re-
ported [21]. Blood was collected in EDTA or heparin
tube with the caution to avoid hemolysis, transported
within 4 hours at room temperature to our lab, and kept
at 4°C. Plasma were then separated at the same day of
sample collecting and frozen at −80°C before analysis.
Internal standard solution of 100 μL (CND Isotopes,
Quebec, Canada) was added to 25 μl plasma. The mix-
ture was vigorously mixed and centrifuged at a speed of
13,300 rcf for 5 min at room temperature and then the
supernatant was transferred to a 96-well plate. Analysis
was performed on a UPLC system with a Xevo TQ MS
detector (Waters, USA). 7-KC and d7-7-KC were de-
tected using positive electrospray ionization through
multiple reaction monitoring modes. The normal range
of 7-KC is 0 ~ 12.3 ng/mL (95th percentile equals to
12.3, Maximum is 22.8) [21].
Clinical observations of patients with confirmed NPC1 or
NPC2 gene mutation
Patient histories, physical examinations, and follow-ups
were conducted by at least one of the listed authors.
Medical history, including the initial onset of symptoms
and the progression of the neurological symptoms until
presentation at our outpatient clinic in Xinhua Hospital,
was based on interviews with parents and patients’ past
medical charts. All subjects were from nonconsangui-
neous families. Patients 6 and 7 were siblings, and the
others were unrelated. We focused on the commonly oc-
curring symptoms/conditions, such as jaundice, hepatos-
plenomegaly, vertical supranuclear gaze palsy, ataxia,
gelastic cataplexy, seizure, gain/loss in psychomotor de-
velopmental milestones, and blood chemistry panels. For
two patients (patients 4 and 11) liver enzyme tests per-
formed in the perinatal period when jaundice was prom-
inent are listed. For the rest of the patients, if multiple
liver enzyme tests were performed during the diseasecourse, the latest tests prior to presentation in our clinic
were included.
Sequencing of genomic DNA
An elevated level of 7-ketocholesterol was a prerequisite
for molecular characterization of the NPC1 or NPC2
genes, where the NPC1 gene has priority over the NPC2
gene. Genomic DNA was extracted from peripheral
blood using the RelaxGene blood DNA isolation kit
(DNA DP319-01, Tiangen Biotech Co. Ltd., Beijing,
China) according to the manufacturer’s protocol. All
exons and flanking regions of the NPC1 gene were amp-
lified using 23 primer pairs with exon 12–13, exon 15–
16 amplified using one primer pair, respectively. The five
exons of the NPC2 gene were amplified by five primer
pairs. All patients’ parental DNA samples were analysed
to explore the mutation origin.
All primer sequences are available on request. All
amplicons were bi-directionally sequenced, and the results
were aligned with the NPC1 gene reference sequence
(NM_000271.4) and the NPC2 gene reference sequence
(XM_005267270.1). The novelty of all mutations were
checked with the database (http://www.hgmd.org/) and
the novel mutations were further checked in 100 normal
Chinese to exclude rare benign variations.
Results
Determination of 7-KC levels
From 302 suspect patients we identified 12 individuals
with marked elevated plasma 7-KC levels, which
spanned from 32 to 602.7 ng/mL, with an average value
276.7 ng/mL (Table 1, Figure 1). These included 10 pa-
tients from group B, 2 patients from group C. These 12
patients were all confirmed to be NP-C by molecular
genetic testing of the NPC1 and NPC2 genes.
The 7-KC in the non-NP-C cases were 5.5 ± 5.2 ng/ml
(mean ± SD, n = 290). The highest 7-KC value in the
non-NP-C group is 30.8 ng/ml, very close to the lowest
7-KC value (32 ng/ml, patient 10) in the NP-C patients.
This was an infant with cholestatic jaundice without
confirmed diagnosis, who was later excluded as NP-C or
a heterozygote of NPC1/NPC2 gene by molecular ana-
lysis. The 7-KC values in the confirmed heterozygotes,
parents of NPC1 patients, were 20.9 ± 17.2 ng/ml
(mean ± SD, n = 6). Since most non-NP-C patients were
not continuously followed in our clinics, we only knew a
few of them with clear diagnosis in the non-NP-C cases.
There was one patient with Tay-Sachs disease, four pa-
tients with Krabbe disease, four patients with adreno-
leukodystrophy, four patients with metachromatic
leukodystrophy, two patients with Leigh syndrome, two
patients with Neonatal intrahepatic cholestasis caused
by citrin deficiency (NICCD), two patients with muco-
polysacharidosis type IIIB and one patient with Wilson
Table 1 Clinical and molecular findings in 12 Chinese NP-C patients
No. Group Gender Initial
manifestation/age





















F frequent falls, 1y delayed motor/neuron
development,
splenomegaly
1 y 4 y NPC1 c.1501G>T +
c.1800delC





2 F splenomegaly, 6 m splenomegaly, global
developmental delay,
diarrhea, seizure at 7 y,
cerebral atrophy on
brain imaging
1 y 8 y NPC2 c.3G>C +
IVS2 + 5G > A





3 M splenomegaly, 1y splenomegaly, frequent
falls when started
independent walking at
1.5 y, congenital cleft lip
and palate, language
delay, gelastic cataplexy
from 2.5 y, positive
family history
1.5 y 3 y NPC1 c.416_417insC +
c.1832A>G

















1 y 5 y 10 m NPC1 c.2177G>C +
c.3734_3735delCT











1 y 8 m 2 y 2 m NPC1 c.2230_2231delGT +
c.3734_3735delCT






6 F frequent falls,1y3m frequent falls when
walking, gelastic cataplexy,
motor regression at 3 y,
splenomegaly
1 y 3 m 7y NPC1 c.1553G>A +
c.2795dupA










1 y 8 m 3y7m NPC1 c.1553G>A +
c.2795dupA
E9 + E18 p.R518Q + p.
Y932X


















9 juvenile M ataxia, 8ys ataxia, progressively loss
of memory, loss of
language at 9 ys, seizure
from 12 y,
8 y 13 y NPC1 c. 1502A>T +
c. 3634G>T
E9 + E24 p.D501V +
p.V1212L



















Table 1 Clinical and molecular findings in 12 Chinese NP-C patients (Continued)
thrombocytopenia
without splenomegaly







16 y 20 y NPC1 c.2366G>A +
c.2972_2973delAG
E15 + E20 p.R789H + p.
Q991RfsX15
34.7 39.6 N.D 32






N.A 14 m NPC1 c.2054T>C +
c.2128C>T







isolated splenomegaly N.A 3y5m NPC1 c.1030del>T +
c.2861C>T
E8 + E19 p.S344KfsX105
+ p.S954L
N.D N.D N.D 232.3



















Figure 1 Plasma 7-KC levels in four subgroups of Chinese NP-C patients.
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NICCD was 22 ng/ml, which was above the border line
and lower than the maximum value in normal reference.
The confirmed NP-C patients were then categorized
into four subtypes based on presence of neurological
symptoms and the age at neurological onset. There wereFigure 2 Plasma 7-KC levels in patients with confirmed alternative diaseven patients in the early-infantile subtype. For the
late-infantile, juvenile, and adult subtypes, each has
one patient respectively. No patient in the perinatal
subtype was identified. Consistent with previous find-
ings, there was a tendency that 7-KC levels inversely
correlated with the age of disease onset althoughgnosis in the non-NP-C patients.
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(Figure 1 and Table 1) [20].
We identified more than half (7/12) of the patients in
our cohort as fulfilling the characteristics of early infant-
ile subtype, which was different from previous reports of
Chinese NP-C patients, where all patients were catego-
rized into late infantile and juvenile subtypes [17,18,23].
This is also the first time that an adult subtype of NP-C
has been reported in Chinese patients.
Two individuals without neurological manifestations
were confirmed to be NP-C (numbers 11 and 12). Verti-
cal supranuclear gaze palsy was absent in these two pa-
tients after repeated careful observation.
Clinical findings of confirmed NP-C patients
In line with previous publications, 10 of 12 patients had
visceral presentations, isolated splenomegaly or hepatos-
plenomegaly. For patient 10, who belonged to the adult
subtype, the spleen was not palpated under the left ribs,
while spleen thickness was increased per ultrasound. For
patient 9, who was a juvenile form of NP-C, the abdom-
inal ultrasound did not detect splenomegaly. Only two
children (patients 4 and 11, 16.7%) had cholestatic liver
disease together with hepatosplenomegaly, which was
strikingly lower than a previous report, where 39% ~ 65%
of NP-C patients had this symptom in infancy [10,16,24].
The neurological symptoms, if present, were always char-
acteristics of ataxia, psychomotor regression, gelastic cata-
plexy, seizure, and psychosis. Bone marrow biopsy has a
high diagnostic value. Foam cells were identified in all pa-
tients who undertook this procedure.
We found that AST was usually mildly elevated
(higher than 40 IU/L, but lower than 100 IU/L), and
ALT was in a normal range (<40 IU/L), except for the
two measurements taken when jaundice presented in pa-
tients 4 and 11. In all of these 10 patients with liver en-
zyme test results available, AST had a significantly
higher value than ALT (average value, 101.3 IU/L verse
32.6 IU/L, p < 0.001).
Genetic examinations
As for the molecular diagnosis of the 12 Chinese NP-C
patients, 11 patients had a defective NPC1 gene, whereas
only one (patient 2) had a defective NPC2 gene. This ob-
servation is consistent with data from other ethnic
groups that the majority of patients have a mutated
NPC1 gene [13,25]. This is also the first time that a new
set of NPC2 gene mutations has been identified in a
Chinese patient. In this patient, a reported mutation
IVS2 + 5G >A [26] and a novel mutation c. 3G >C (p.M1I)
have been identified.
Both mutant alleles were found on the NPC1 gene from
11 patients (Table 1). Surprisingly, 10 (10/22, 45%) were
small deletions/insertions, which were presumed to causeframe shifts and premature protein truncations (Figure 3).
Except for a novel intronic mutation c.2912-3C >G, pre-
dicted to alter the splicing acceptor site of intron 19 by
ASSP (http://wangcomputing.com/assp/index.html) and
MutationTaster (http://www.mutationtaster.org/), the rest
of the 11 mutations (11/22, 50%) were exonic point
changes resulting in codon replacement. Nearly all of the
mutations were distributed in axons post 7, except one in
exon 3 (Table 1).
The majority of small deletions/insertions were re-
ported here for the first time, including c.1800delC,
c.416_417insC, c.2302_2303insG, c.2230_2231delGT,
c.1030delT, and c.2795dupA. Two small deletions,
c.3734_3735delCT and c.2972_2973delAG, had been
published previously [27,28]. The c.3734_3735delCT
was the only recurring mutant in this group, presenting
twice (patients 4 and 5), indicating that this may be a com-
paratively common mutation in the Chinese population.
Among exonic point changes, three mutants were pre-
viously published, c. 1501G>T (p.D501Y) [17], c.3634G>T
(p.V1212L) [18], and c.2861C>T (p.S954L) [29]. We did
not find the hot mutations including p.I1061T, p.P1007A,
and p.G992W that are the most recurrent in the Western
population [13]. In addition to one patient in this paper,
four unrelated Chinese patients with p.V1212L in hetero-
zygous state have been described [11,18], indicating that
this may be another comparatively common mutation in
the Chinese population.
The seven novel exonic point mutations were c.
1502A>T (p.D501V), c.1553G>A (p.R518Q), c.A1832A>G
(p.D611G), c.2054T>C (p.I685T), c.2128C>T(p.Q710X),
c.2177G>C (p.R726T), c.2366G>A (p.R789H). Except for
the stop codon mutation p.Q710X, the rest were exonic
missense mutations, which were highly likely to be patho-
genic, as predicted by MutationTaster. All novel mutations
have been submitted to the public database ClinVar.
Discussion
The current diagnosis of NP-C was mainly filipin stain-
ing for unesterified cholesterol of cultured fibroblasts
obtained through invasive skin biopsy. The positive indi-
viduals were then followed by genetic testing. However,
filipin assay is time-consuming and cannot discriminate
some cases with a “variant” filipin pattern from normal
controls [5]. The filipin assay is performed in only a few
centres world-wide. Some small diagnostic centres per-
form mutation analysis alone, where two mutant alleles
are necessary to confirm the diagnosis. But in about 10-
15% cases, routine DNA sequence failed to identify mu-
tations on both alleles, especially when there were large
deletions involving NPC1 [30]. Furthermore, mutation
analysis alone could not differentiate disease-causing al-
leles from polymorphisms when confronting unreported
nucleotide changes.
Figure 3 Localization of mutation identified in 12 Chinese NP-C patients draw on the schematic NPC1 protein model [29]. Red circle:
novel exonic point mutations; Red rectangle: novel small insertion/deletions; Green square: reported exonic point mutations; Green rectangle:
reported small insertion/deletions.
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increased in the plasma of human NPC1 subjects and
NPC1 mouse model, and were decreased under therapy,
they were regarded as NPC1 disease-specific biochemical
markers and will replace the filipin assay as the diagnos-
tic standard for NPC1 disease. Since 3β,5α,6β-triol was
not readily detectable by a non-derivatized method, we
concentrated on 7-KC detection [21]. We found that 7-
KC was in normal range in patients with MPS II, GSD
II, Gaucher disease, Metachromatic leukodystrophy, and
Krabbe disease, and was markedly elevated in patients
with ASM deficient NPD and NPC disease [21]. Here we
employed this test in populations with hepatosplenome-
galy/isolated splenomegaly, excluding ASM deficient
NPD, and in populations with neonatal cholestasis, phy-
chomotor regression/retardation, where NP-C disease
may have a comparatively high prevalence.
Since 7-KC assay could be performed in a high
throughput manner in our lab, we did not calculate
score of the suspicion index [31] when recruiting sub-
jects to this study to avoid missing atypical patients. We
identified 12 individuals with high levels of plasma 7-
KC, who were then confirmed to be NP-C by genetic
testing, indicating a strong specific correlation between
elevated 7-KC and NP-C. Our data also demonstrate
that one NP-C patient due to NPC2 gene mutation also
had high 7-KC levels, which was reasonable considering
the concert signaling pathway of NPC1 and NPC2. Since
the 7-KC value in the adult type could be as low as those
in the NPC1 carriers, in the highly suspect adult pa-
tients, even if the detected 7-KC value is at the borderline, it is still necessary to follow up with the NPC1 and
NPC2 gene analysis to avoid any potential misdiagnosis.
The 7-KC positive rate is about 4% in our tested popu-
lation. It seems lower than reported prevalence of NPC1
disease that approaches 8% in neonates with jaundice in
one medical centre [6]. The comparatively low positive
rate may reflect the loose criteria in subject recruiting or
the true lower prevalence of NP-C in Chinese than that
in Western countries since there were no hot mutations
in reported Chinese cases, including cases in this report.
As expected, with this diagnostic flowchart, we identi-
fied two patients (numbers 11 and 12) without obvious
neurological impairment. Since current data are suggest-
ive of a correlation of high 7-KC with disease severity,
these two patients were predicted to have an early or late
infantile type with 7-KC 456.3 ng/ml and 232.3 ng/mL,
respectively. Further clinical following-up will be needed
to confirm this speculation. But if the therapeutic drug
were available to these two patients at this stage of the
disease, their prognosis might be much better than its
natural course [12].
Most publications emphasized the neurodegeneration
characteristics of NP-C disease, apart from the pro-
longed jaundice in the neonatal period. In a study of
paediatric NP-C disease with particular reference to liver
disease, half of the NP-C children who survived the neo-
natal jaundice had persistent liver disease with elevated
aminotransferase values while the other half had normal
aminotransferase activity. In NP-C cat and mouse
models, elevated ALT and AST were also consistently
observed [32,33]. These data support liver involvement
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addition to its distinctive neurological degeneration.
We also paid special attention to routine biochemical
panels. We observed that both ALT and AST were ele-
vated in NP-C patients with jaundice (patient 4 and 11),
while only mildly elevated AST was observed in NP-C
patients without jaundice. In both situations, the AST
was always higher than ALT. Elevated AST was consist-
ently observed in a patient without hepatosplenomegaly
(patient 9). It is well known that ALT is a cytosolic en-
zyme specific for increases in hepatocellular permeabil-
ity, and AST is located in both the cytosol and
mitochondria, which would increase in serum with he-
patocellular or muscle damage. Mildly elevated AST
with normal ALT may mean more severe damage of
unesterified cholesterol or its byproduct oxysterols to
hepatocyte mitochondria than to hepatocyte membrane.
Cellular oxidative stress to mitochondria had been dem-
onstrated in NPC1-deficient human cells [34] and NP-C
mouse models [35], which provided a basis for our
hypothesis.
Our data showed that small deletions/insertions con-
stituted nearly half of all mutant alleles, which different
from results obtained in previous molecular studies of
Chinese NP-C patients and other ethnic groups, where
point mutations leading to amino acid missense changes
constituted the majority of all mutations [15,17,18,25].
Because frame shift mutations correlated with the most
severe neurological presentation, it is consistent with the
patients’ clinical courses that six out of 11 NPC1 mu-
tated patients (patients 1, 3, 4, 5, 6, and 7) belonged to
the early infantile form. Our data may be biased towards
very young children, since two third individuals in the
whole cohort were under 6 years old.
Four point mutations on the sterol-sensing domain, p.
I685T, p.Q710X, p.R726T, and p.R789H, were detected.
The combination of a small deletion c.3734_3735delCT
and p.A726T in an early infantile form of NP-C disease
(patient 4) corroborated that missense mutations located
in the sterol-sensing domain are very deleterious [29].
While two severe mutations, c.2972_2973delAG and p.
R789H, were detected in an adult form (patient 10).
These observations showed the complexity of phenotype
and genotype correlation in the NP-C disease. Two mu-
tant alleles of patients 11, p.I685T and p.Q710X, were
on the sterol-sensing domain, indicating that he may ex-
perience a severe form of NP-C. The high 7-KC level
(456.3 ng/ml) of this patient provided additional evi-
dence of a severe clinical course.
Summary
With the help of the plasma biomarker 7-KC, we had
made rapid diagnoses of NP-C in a cohort of Chinese
patients. If plasmatic 7-KC assay becomes widely availablein the future, it might be used as a first screening for all
types of Niemann-Pick disease. In addition to the charac-
teristic somatic and neurologic presentations and foamy
cells in bone marrow biopsy, the mildly elevated AST
levels compared with normal ALT levels may be easy
recognizable serum changes in NP-C disease without cho-
lestasis before screening of 7-KC. A total of 14 novel mu-
tations in the NPC1 gene and one novel mutation in the
NPC2 gene have been identified. With increasing aware-
ness of this devastating disease, and using the rapid and
reliable plasma biomarker 7-KC, we envision that more
patients should receive a timely diagnosis and treatment
in the future.
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